Get our July/August issue now

available for iOS, Android and web


Latest issue

 

INTERVIEW
The head-in-the-sand approach stops here
PharmaTimes Magazine talks to the new ABPI president Jonathan Emms about speaking out on behalf of patients

GENOMICS
Busting the niche: the future of genomics
The challenge is for pharma to adapt and start developing more specialised drugs

REAL-WORLD DATA
Get real

What does pharma need to know about putting real-world data into practice?

COUNTRY FOCUS
Nuts about Brazil?
Does the Latin American country still retain the same allure it once did for life sciences? 

PATIENT ENGAGEMENT
When delivering treatment is not enough
How can patients be encouraged to participate in their own care?

HEALTH FOCUS
Sticking with statins
Saviour or side-effect nightmare? 

PATIENT FILES
“Listening to patients is critical”
How insight into living with a rare disease can help improve healthcare

Click here to see the latest PharmaTimes Magazine

To subscribe go to www.pharmatimes.com/subscribe; digital available from:

download on the app store get it on google play

Outcomes: a gamechanger for pharma

Patient-recorded outcome measures are likely to become a key part of how healthcare is provided, funded and managed. But is industry ready?

Healthcare Writer Lynne Taylor

The British government’s determination to place health outcomes at the heart of NHS decision-making presents UK-based drugmakers with a unique and potentially huge advantage over their global competitors.

Working in collaboration with the NHS to identify a product’s true value – in other words its value to the patient – has the potential to boost levels of medicines uptake and could also lead to products arriving earlier to market, both in the UK and overseas, a PharmaTimes business meeting was told recently. Leading these potentially game-changing opportunities is the NHS patient-recorded outcome measures programme, which began in 2009.

Innovative drugmakers have included PROMs in their clinical trials for many years, and the data have also long been used in observational studies and population health surveys. “We have decades of experience using these instruments and pharma is way ahead of the game. The fact they are now being measured in healthcare systems changes everything,” Professor Nancy Devlin, research director at the Office of Health Economics told the meeting. Indeed, PROMs are likely to become a key part of how all healthcare is provided, funded and managed, The King’s Fund healthcare policy think-tank has forecast.

So what exactly are PROMs and why should this matter to pharma? You can find out by reading the full article online here

See what's coming up in the March issue [PDF]

Visions 2014 supplement

Contents:

R&D
Creating a balance between
reimbursement and innovation

Real-world data
How to plan early

NHS reform
What more does pharma need to do?

PharmaTweets
We asked you what the big developments in 2014 will be?

Change is key to opportunity
What to adapt for

Salesforce effectiveness
Future-proofing the sales team

Myeloma research
An example of a new R&D model

Soundbites
Visions in a nutshell

The complete Visions 2014 supplement PDF is available to download

 

Subscription is free to qualifying UK subscribers

To read articles in full and features in the magazine, why not subscribe

Reprints available.

Average circulation Jan - Dec 2013: 23,178

JobSearch


Head-to-Head Video

 

Website Search


Search News Search Magazine
 

Technoblog


Elert Signup!